GLB 004
Alternative Names: GLB-004Latest Information Update: 15 Apr 2024
Price :
$50 *
At a glance
- Originator GluBio Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Renal cell carcinoma
Most Recent Events
- 05 Apr 2024 Early research in Renal cell carcinoma in USA (unspecified route) prior to April 2024 (GluBio Therapeutics pipeline, April 2024)